Mindful innovation: driven by a commitment to patients and their families.
Patients are top of mind as we work to develop ganaxolone.
Marinus Pharmaceuticals, Inc. is committed to improving the lives of patients suffering from drug-resistant seizures and neuropsychiatric disorders through the development of a new and safe drug candidate, ganaxolone, which offers an alternative treatment option for acute and chronic illnesses.
Ganaxolone is a drug candidate designed to exhibit antiepileptic, anxiolytic, antidepressant, and sedative activity by virtue of its GABAA receptor modulating properties.
Ganaxolone is being developed in three different dose forms (IV, capsule, and liquid) intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings where there is a mechanistic rationale for ganaxolone to provide a benefit.
Mindful innovation for improved health.
To discover, develop, and commercialize life changing therapies for children and adults affected by CNS disorders and rare diseases.
How We Work
Our goal is to maximize the value of ganaxolone as a first-in-class innovative neuropsychiatric therapy with a portfolio of diversified indications.
With orphan drug designation status from the FDA, we are currently evaluating ganaxolone in children with debilitating and rare genetic epilepsies (Marigold study) and patients suffering from life-threatening refractory status epilepticus. Ganaxolone is also being evaluated in mothers suffering from postpartum depression (Magnolia and Amaryllis studies).
The Marinus team is committed to developing new treatments that make a meaningful difference in the lives of the patients and families we serve.
We partner closely with patient advocacy groups for patients suffering from epilepsy and neuropsychiatric disorders, and are dedicated to developing treatments that meet their unmet medical needs and ultimately, improve their lives.
“Our goal at Marinus is to improve the lives of patients and families who suffer from neuropsychiatric disorders. Ganaxolone utilizes an endogenous mechanism of action to modulate the GABAA system in the brain.”
Christopher M. Cashman, CEO
Partnering with Marinus
Marinus is actively seeking opportunities to expand our portfolio in orphan neuropsychiatric disorders through licensing and partnering.
INTERESTED IN PARTNERING?
For more information about partnering or collaborating with Marinus Pharmaceuticals, please contact:
Explore Patient Resources
Find helpful information and patient networks, as well as clinical trial opportunities.